Incidence of Autoimmune Diseases in Children with Atopy Treated with Dupilumab - PubMed
7 hours ago
- #Atopic children
- #Autoimmune diseases
- #Dupilumab
- Dupilumab treatment in atopic children showed a modestly higher incidence of autoimmune diseases compared to untreated children.
- The adjusted incidence rate difference for any autoimmune disease was 2.47 per 1,000 person-years, mainly due to cutaneous autoimmune diseases (rate difference 2.20 per 1,000 person-years).
- Within 4 years of treatment, dupilumab-treated children had 1.45-fold higher rates of any autoimmune disease and 1.57-fold higher rates of cutaneous autoimmune disease.
- The study used a retrospective cohort design with data from 10 PEDSnet academic health systems, including children aged 6-17 with atopy.
- Findings address knowledge gaps about clinical outcomes of dupilumab in atopic children, highlighting a potential risk of autoimmune manifestations.